GC Corp.

SEC Form 4 insider trading activity

GC Corp. has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: May 28, 2026.

On the most recent filing, GC Corp. is listed as 10% Owner at Artiva Biotherapeutics, Inc. Inside the rolling window, GC Corp. reported 1 open-market purchase totaling $16.5M in ARTV and no open-market sales.

Companies traded

Other insiders at ARTV

Insider Buying

$16.5M

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
ARTVPurchase$16.5MMay 28SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has GC Corp. made?

GC Corp. has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company since 2026.

Which companies does GC Corp. trade?

GC Corp. has filed SEC Form 4 disclosures for 1 company, including ARTV.

When was GC Corp.'s most recent SEC Form 4 filing?

GC Corp.'s most recent SEC Form 4 filing on Tracefour is dated May 28, 2026.

What is GC Corp.'s total buy and sell value in the current window?

Inside the rolling retention window, GC Corp. bought $16.5M and sold $0 based on SEC Form 4 filings.

What was GC Corp.'s largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 1,432,291 ARTV shares on 2026-05-11, worth $16.5M, per SEC Form 4 filings.